The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies

Eitemau Tebyg

• Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
  gan: Piotrowska, Zofia, et al.
  Cyhoeddwyd: (2015)
• Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third Generation EGFR Inhibitor
  gan: Piotrowska, Zofia, et al.
  Cyhoeddwyd: (2015)
• Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers
  gan: Khandekar, Melin J., et al.
  Cyhoeddwyd: (2018)
• Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
  gan: Marcar, Lynnette, et al.
  Cyhoeddwyd: (2019)
• The Anticipated Next Season of EGFR Inhibitors
  gan: Sequist, Lecia V.
  Cyhoeddwyd: (2015)